Kura Oncology stock: UBS keeps Buy rating and USD 15 target
Published on 10/30/2026 at 20:19 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSAnalyst stance and operating context
- UBS maintained a Buy rating on Kura Oncology after analyst David Dai's review.
- Kura reported second-quarter revenue of USD 20.87 million and a GAAP net loss of USD 68.33 million.
UBS analyst David Dai maintained a Buy rating on Kura Oncology and set a USD 15.00 price target on Thursday, October 29, according to Markets Insider. The report identifies the target as an analyst assessment rather than company guidance.
UBS keeps positive stance
The renewed Buy rating follows Kura's latest reported quarter, which ended June 30. The company generated USD 20.87 million in revenue and recorded a GAAP net loss of USD 68.33 million, compared with revenue of USD 15.29 million and a GAAP net loss of USD 66.12 million in the year-earlier quarter, according to the report.
The figures underline Kura's commercial-stage transition while also showing that the company remains loss-making. For investors, UBS's target is denominated in US dollars, whereas the European trading quote is in euros, so the two figures are not a direct same-currency comparison.
Kura Oncology stock traded at 9.09 euros on Lang & Schwarz at 8:09 p.m. Berlin time on Friday, October 30. Investors can follow the real-time quote of Kura Oncology stock.
Kura Oncology at a glance
- Company: Kura Oncology, Inc.
- ISIN: US50127T1097
- Ticker: KURA
- Lang & Schwarz quote: 9.09 euros on October 30, 2026, at 8:09 p.m. Berlin time
- UBS rating: Buy
- UBS price target: USD 15.00
Investors can track the broader US equity market through the S&P 500 market overview.
More news and analyses are available on Kura Oncology stock.
